These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31923206)

  • 1. High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.
    Ohkuma R; Yada E; Ishikawa S; Komura D; Ishizaki H; Tamada K; Kubota Y; Hamada K; Ishida H; Hirasawa Y; Ariizumi H; Satoh E; Shida M; Watanabe M; Onoue R; Ando K; Tsurutani J; Yoshimura K; Yokobori T; Sasada T; Aoki T; Murakami M; Norose T; Ohike N; Takimoto M; Izumizaki M; Kobayashi S; Tsunoda T; Wada S
    PLoS One; 2020; 15(1):e0226707. PubMed ID: 31923206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer.
    Ohkuma R; Yada E; Ishikawa S; Komura D; Kubota Y; Hamada K; Horiike A; Ishiguro T; Hirasawa Y; Ariizumi H; Shida M; Watanabe M; Onoue R; Ando K; Tsurutani J; Yoshimura K; Sasada T; Aoki T; Murakami M; Norose T; Ohike N; Takimoto M; Kobayashi S; Tsunoda T; Wada S
    Int J Oncol; 2021 Jan; 58(1):57-69. PubMed ID: 33367933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer.
    Ohkuma R; Yada E; Ishikawa S; Komura D; Kubota Y; Hamada K; Horiike A; Ishiguro T; Hirasawa Y; Ariizumi H; Shida M; Watanabe M; Onoue R; Ando K; Tsurutani J; Yoshimura K; Sasada T; Aoki T; Murakami M; Norose T; Ohike N; Takimoto M; Kobayashi S; Tsunoda T; Wada S
    Oncol Rep; 2020 Jul; 44(1):252-262. PubMed ID: 32627041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression of olfactomedin 4 correlates with poor prognosis in smoking patients with non-small cell lung cancer.
    Su W; Luo L; Wu F; Lai Z; Li X; Xie Z; Tang Z; Yang Z; Liang R
    Hum Pathol; 2015 May; 46(5):732-8. PubMed ID: 25771901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.
    Li H; Kim C; Liu W; Zhu J; Chin K; Rodriguez-Canales J; Rodgers GP
    Int J Cancer; 2020 Mar; 146(5):1346-1358. PubMed ID: 31241767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olfactomedin-4 in digestive diseases: A mini-review.
    Wang XY; Chen SH; Zhang YN; Xu CF
    World J Gastroenterol; 2018 May; 24(17):1881-1887. PubMed ID: 29740203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olfactomedin 4 associates with expression of differentiation markers but not with properties of cancer stemness, EMT nor metastatic spread in colorectal cancer.
    Jaitner S; Pretzsch E; Neumann J; Schäffauer A; Schiemann M; Angele M; Kumbrink J; Schwitalla S; Greten FR; Brandl L; Klauschen F; Horst D; Kirchner T; Jung A
    J Pathol Clin Res; 2023 Jan; 9(1):73-85. PubMed ID: 36349502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of the olfactomedin 4 gene is associated with progression of human prostate cancer.
    Li H; Rodriguez-Canales J; Liu W; Zhu J; Hanson JC; Pack S; Zhuang Z; Emmert-Buck MR; Rodgers GP
    Am J Pathol; 2013 Oct; 183(4):1329-38. PubMed ID: 24070418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olfactomedin-related proteins 4 (OLFM4) expression is involved in early gastric carcinogenesis and of prognostic significance in advanced gastric cancer.
    Jang BG; Lee BL; Kim WH
    Virchows Arch; 2015 Sep; 467(3):285-94. PubMed ID: 26070873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer.
    Luo Z; Zhang Q; Zhao Z; Li B; Chen J; Wang Y
    J Cancer Res Clin Oncol; 2011 Nov; 137(11):1713-20. PubMed ID: 21904905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex Determining Region Y Box 9 Induces Chemoresistance in Pancreatic Cancer Cells by Induction of Putative Cancer Stem Cell Characteristics and Its High Expression Predicts Poor Prognosis.
    Higashihara T; Yoshitomi H; Nakata Y; Kagawa S; Takano S; Shimizu H; Kato A; Furukawa K; Ohtsuka M; Miyazaki M
    Pancreas; 2017; 46(10):1296-1304. PubMed ID: 28984791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer.
    Liu W; Rodgers GP
    Cancer Metastasis Rev; 2016 Jun; 35(2):201-12. PubMed ID: 27178440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.
    Valo I; Raro P; Boissard A; Maarouf A; Jézéquel P; Verriele V; Campone M; Coqueret O; Guette C
    Proteomics; 2019 Nov; 19(21-22):e1800446. PubMed ID: 31318138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-103 regulates triple negative breast cancer cells migration and invasion through targeting olfactomedin 4.
    Xiong B; Lei X; Zhang L; Fu J
    Biomed Pharmacother; 2017 May; 89():1401-1408. PubMed ID: 28320108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.
    Ma H; Tian T; Liang S; Liu X; Shen H; Xia M; Liu X; Zhang W; Wang L; Chen S; Yu L
    Oncotarget; 2016 Mar; 7(9):10594-605. PubMed ID: 26871282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling.
    Guo LL; He ZC; Yang CQ; Qiao PT; Yin GL
    BMB Rep; 2015 Nov; 48(11):630-5. PubMed ID: 26303970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells.
    Kobayashi D; Koshida S; Moriai R; Tsuji N; Watanabe N
    Cancer Sci; 2007 Mar; 98(3):334-40. PubMed ID: 17270022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quantitative proteomics study on olfactomedin 4 in the development of gastric cancer.
    Ran X; Xu X; Yang Y; She S; Yang M; Li S; Peng H; Ding X; Hu H; Hu P; Zhang D; Ren H; Wu L; Zeng W
    Int J Oncol; 2015 Nov; 47(5):1932-44. PubMed ID: 26398045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer.
    Kawano M; Mabuchi S; Matsumoto Y; Sasano T; Takahashi R; Kuroda H; Kozasa K; Hashimoto K; Isobe A; Sawada K; Hamasaki T; Morii E; Kimura T
    Sci Rep; 2015 Dec; 5():18217. PubMed ID: 26666576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.